Local tumor control and DNA-PK activity of peripheral blood lymphocytes in prostate cancer patients receiving radiotherapy. (7th October 2016)

• Record Type: Journal Article
• Authors: Someya, Masanori; Hasegawa, Tomokazu; Hori, Masakazu; Matsumoto, Yoshihisa; Nakata, Kensei; Masumori, Naoya; Sakata, Koh-ichi
• Is Part Of: Journal of radiation research. Volume 58:Number 2(2017:Mar.)
• Page Start: 225
• Page End: 231
• Publication Date: 2016-10-07
• Subjects: prostate cancer -- radiotherapy -- predictive assay -- late urinary toxicity -- DNA-PK activity; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrw099
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: Repair of DNA damage is critical for genomic stability, and DNA-dependent protein kinase (DNA-PK) has an important role in repairing double-strand breaks. We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy. A total of 69 patients with localized adenocarcinoma of the prostate participated in this study. Peripheral blood was collected 2 years or later after radiotherapy and centrifuged, then DNA-PK activity was measured by a filter binding assay. The high DNA-PK activity group had a significantly higher PSA relapse–free survival rate than the low DNA-PK activity group. The 10-year PSA relapse–free survival was 87.0% in the high DNA-PK activity group, whereas it was 52.7% in the low DNA-PK activity group. Multivariate analysis showed the Gleason score and the level of DNA-PK activity were significant predictors of PSA relapse after radiotherapy. In addition, the low DNA-PK activity group tended to have a higher incidence of Grade 1–2 urinary toxicity than the high DNA-PK activity group. Prostate cancer patients with low DNA-PK activity had a higher rate of PSA relapse and a higher incidence of urinary toxicity. DNA-PK activity in PBLs might be a useful marker for predicting PSA relapse and urinary toxicity, possibly contributing to personalized treatment of prostate cancer.